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The CARMA1/CARD11-BCL10-MALT1 (CBM) com-
plex bridges T and B cell antigen receptor (TCR/
BCR) ligation to MALT1 protease activation and ca-
nonical nuclear factor kB (NF-kB) signaling. Using
unbiased mass spectrometry, we discover multiple
serine phosphorylation sites in the MALT1 C termi-
nus after T cell activation. Phospho-specific anti-
bodies reveal that CBM-associated MALT1 is tran-
siently hyper-phosphorylated upon TCR/CD28
co-stimulation. We identify a dual role for CK1a as
a kinase that is essential for CBM signalosome as-
sembly as well as MALT1 phosphorylation. Although
MALT1 phosphorylation is largely dispensable for
protease activity, it fosters canonical NF-kB
signaling in Jurkat andmurine CD4 T cells. Moreover,
constitutive MALT1 phosphorylation promotes sur-
vival of activated B cell-type diffuse large B cell lym-
phoma (ABC-DLBCL) cells addicted to chronic BCR
signaling. Thus, MALT1 phosphorylation triggers
optimal NF-kB activation in lymphocytes and sur-
vival of lymphoma cells.
INTRODUCTION
Recognition of antigens by cognate antigen receptors expressed
on T andB lymphocytes represents the initial step inmounting an
adaptive immune response. In lymphoid cells, the CARMA1/
CARD11-BCL10-MALT1 (CBM) complex bridges T or B cell an-
tigen receptor (TCR/BCR) proximal signaling to the canonicalCell
This is an open access article undnuclear factor kB (NF-kB) pathway and c-Jun N-terminal kinase
(JNK) activation (Meininger and Krappmann, 2016). Through its
scaffolding and proteolytic activities, MALT1 performs a dual
role in the CBM complex (Jaworski and Thome, 2016). As an
adaptor, MALT1 associates with TRAF6 and potentially other
E3 ligases, which catalyze MALT1 poly-ubiquitination on
multiple lysine residues in the C terminus, and thereby promotes
recruitment of TAK1 and NEMO/IKKb kinases to activate NF-kB
and JNK signaling (Oeckinghaus et al., 2007; Sun et al., 2004).
Two alternative splice variants of MALT1 (MALT1A andMALT1B)
have been identified that differ in their TRAF6-binding ability,
thereby modulating downstream signaling strength and
T cell activation (Meininger et al., 2016). The protease function
of MALT1 is activated after antigenic stimulation of T cells,
requiring mono-ubiquitination on K644 in MALT1A (Coornaert
et al., 2008; Pelzer et al., 2013; Rebeaud et al., 2008). MALT1
protease activity does not directly control signaling downstream
of the CBM complex (Bornancin et al., 2015; Gewies et al., 2014;
Jaworski et al., 2014), but cleavage of MALT1 substrates, such
as A20, BCL10, CYLD, HOIL-1, RelB, Regnase-1 (MCPIP1), or
Roquin1/2, has been associated with various T cell functions
(Coornaert et al., 2008; Hailfinger et al., 2011; Jeltsch et al.,
2014; Klein et al., 2015; Rebeaud et al., 2008; Staal et al.,
2011; Uehata et al., 2013). MALT1 scaffolding and protease
activities are also critical for survival of B cells derived from
activated B cell-type diffuse large B cell lymphomas (ABC-
DLBCLs) that are addicted to chronic BCR signaling or onco-
genic CARD11 mutations (Ferch et al., 2009; Hailfinger et al.,
2009; Ngo et al., 2006).
Several protein kinases regulate the CBM complex by
phosphorylating CARD11 and BCL10, thereby positively or
negatively affecting T cell activation (Gehring et al., 2018; Mei-
ninger and Krappmann, 2016). However, whether MALT1 isReports 29, 873–888, October 22, 2019 ª 2019 The Author(s). 873
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. MALT1 Is Phosphorylated on Multiple C-Terminal Serine Residues after T Cell Stimulation
(A) Overview of identified MALT1 phosphorylation peptides in LC-MS/MS. PSM, peptide-spectrum-match. See also Figures S1A and S1B.
(B) MALT1B protein sequence with identified phospho-peptides highlighted in red boxes and phospho-serines in red.
(legend continued on next page)
874 Cell Reports 29, 873–888, October 22, 2019
prone to regulatory phosphorylation after T cell stimulation has
not been investigated to date. A large-scale proteomic study
identified putative phosphorylations in murine MALT1 after
BCR ligation, but the sites have not been confirmed or investi-
gated functionally (Satpathy et al., 2015).
Here, we used mass spectrometry and identified multiple
C-terminal serine phosphorylations in MALT1 after T cell
activation. We demonstrate that MALT1 is hyper-phosphory-
lated within the CBM complex and that MALT1 phosphorylation
regulates TCR/CD28-induced canonical NF-kB signaling as well
as survival of BCR-addicted ABC-DLBCL cells.
RESULTS
MALT1 Hyper-Phosphorylation in Activated T Cells
We performed liquid chromatography coupled to tandem
mass spectrometry (LC-MS/MS) to identify phospho-peptides
in MALT1 before and after T cell stimulation. To enrich MALT1,
we used MALT1 knock out (KO) Jurkat T cells that had been
stably reconstituted with human MALT1A C-terminally tagged
with a FLAG-StrepII-tag epitope (MALT1A-FS). MALT1A-FS
was expressed at endogenous levels and rescued TCR/
CD28 signaling and NF-kB activation in MALT1-deficient
Jurkat T cells (Meininger et al., 2016). Strep-Tactin pull-down
(ST-PD) led to efficient depletion of MALT1 from the extracts
(Figure S1A). Further, we enriched phospho-peptides by tita-
nium dioxide. No MALT1 phospho-peptides were detected in
unstimulated Jurkat T cells, but we identified three MALT1
phospho-peptides in phorbol 12-myristate 13-acetate (PMA)/
ionomycin (P/I)-treated Jurkat T cells, covering a total of
five phosphorylated serine residues that were detected with
high confidence (false discovery rate [FDR] < 1%) (Figures
1A and S1B). The putative MALT1 phosphorylation sites
correspond to S570, S573, S656, S660, and S814 in human
MALT1A or S559, S562, S645, S649, and S803 in human
MALT1B (Figures 1A–1C). Interestingly, two identified pep-
tides indicated pairwise phosphorylation at serines in close
proximity (S559/S562 and S645/S649 in MALT1B). In the
C-terminal phospho-peptide, we also detected a second
putative phosphorylation on S805 in MALT1B (S816 in
MALT1A) but with lower phosphoRS site probability (Figures
1B and 1C). Nevertheless, the data indicate that the C-termi-
nal phospho-peptide may also contain two adjacent phos-
phorylation sites on S814/S816 and S803/S805 in MALT1A
and MALT1B, respectively. We did not detect dual modified
peptides, which we attribute to low abundance and detection
thresholds. Because functional analyses were performed with
human MALT1B, we subsequently refer to the amino acid po-
sition of MALT1B, which lacks exon 7 (aa 309–319) (Meininger
et al., 2016).(C) Domain organization of MALT1B protein with positions of phosphorylation sit
(D) Positions of phospho-serines in the crystal structure of ligand-bound MALT1
(E) Evolutionary conservation of identified MALT1 phosphorylation sites in mamm
(F–H) Generation and validation of antibodies against phosphorylated MALT1B S
phospho-defective S/A mutant and l-protein phosphatase (PP) treatment. Phos
MALT1 western blot (WB).
(I) Detection of phosphorylated MALT1B S562 in primary human CD4 T cells isoAll phosphorylation sites map to the region of the MALT1
C-terminal in the paracaspase domain (Figure 1C). In the crystal
structure of the MALT1paracasp-Ig3 fragment, S559 and S562 are
located at the start of the linking a-helix that connects the para-
caspase and the Ig3 domain (Figure 1D). S645 and S649 are
within a connecting loop in the Ig3 domain and near to K633,
which is targeted by mono-ubiquitination (Pelzer et al., 2013).
S803 and S805 are in the C terminus of MALT1 adjacent to the
only functional TRAF6 binding motif (T6BM) in MALT1B,
T6BM3 (PVETTD aa 793–798) (Figure 1C) (Meininger et al.,
2016; Sun et al., 2004). With the exception of human S562, which
is not present in rodentMALT1, the phospho-sites are conserved
in mammals (Figure 1E).
To confirm MALT1 phosphorylation and to investigate the
regulation, we generated monoclonal antibodies that recog-
nize the phosphorylated serines, which were identified with
high confidence (Figure 1A): pS562 (clone 24E9), pS649 (clone
29E12), and pS803 (clone 24A4). Phospho-specific MALT1
detection was assessed by 20 min of P/I stimulation in
MALT1 KO Jurkat T cells reconstituted with MALT1B-FS. All
three phospho-specific antibodies reacted strongly with
slower-migrating, highly modified MALT1B wild type (WT)
only after T cell stimulation (Figures 1F–1H). Detection with
anti-pS562-, anti-pS649-, and anti-pS803-MALT1 antibodies
was severely reduced when phospho-defective MALT1 mu-
tants S562A, S649A, and S803/805A were transduced,
respectively. Phosphorylation at S562 and S649 was detected
by western blot after Strep-Tactin pull-down (ST-PD) of
MALT1B-SF and was completely abolished by phosphatase
treatment, confirming detection of phospho-MALT1 (Figures
1F and 1G). MALT1 pS803 was only recognized after anti-
pS803-MALT1 immunoprecipitation (IP) followed by anti-
MALT1 western blot, indicating that the antibody preferably
reacts with pS803 in its native conformation (Figure 1H).
Although the anti-pS562-MALT1 antibody exclusively de-
tected hyper-modified and phosphorylated MALT1 (Figure 1F),
anti-pS649- and anti-pS803-MALT1 antibodies still retained
some activity against unphosphorylated MALT1 (Figures 1G
and 1H). In the case of the anti-pS649-MALT1 antibody,
detection was phosphatase insensitive but was lost by an
S649A exchange, proving that the antibody also detects un-
modified S649. In conclusion, we have been able to generate
three antibodies that allow monitoring of MALT1
phosphorylation status.
To confirm that MALT1 is also phosphorylated in primary
T cells, we stimulated human CD4 T cells purified from donor
blood with P/I for 20 min (Figure 1I). With MALT1-IP, we de-
tected phosphorylation at S562 after T cell stimulation,
demonstrating that MALT1 is phosphorylated in primary
T cells. Thus, by LC-MS/MS and phospho-specific antibodies,es.
para-Ig3 fragment (PDB: 4I1P).
als.
562 (F), S649 (G), and S803 (H). Phosphorylation specificity was verified with
phorylated MALT1B S803 is detected by the antibody after anti-pS803-IP and
lated from donor blood and stimulated with P/I.
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we were able to identify T cell stimulation-dependent phos-
phorylation of multiple serine residues in the C terminus of
MALT1B.
MALT1 Phosphorylation Occurs within the Active CBM
Complex
We next used the pMALT1 antibodies to examine T cell stim-
ulation-dependent phosphorylation kinetics of endogenous
MALT1 (Figure 2). After stimulation of Jurkat T cells with
anti-CD3/CD28 antibodies or P/I, we measured MALT1 phos-
phorylation as well as CARD11 activation, CBM complex as-
sembly/disassembly, and NF-kB signaling over a time course
up to 8 h (Figures 2A and 2B). Intriguingly, although CARD11
S645 phosphorylation and BCL10-MALT1 recruitment to
CARD11 were visible after 2 min of anti-CD3/CD28 or P/I
stimulation, MALT1 phosphorylation at the three sites was de-
layed and peaked after 20–30 min. MALT1 phosphorylation
coincided with the onset of IkBa degradation and the induc-
tion of canonical NF-kB signaling. Although we did not
observe significant differences in the initial phosphorylation
of the distinct sites, the duration of MALT1 S562 phosphoryla-
tion was sustained and still detectable after 1–8 h of stimula-
tion. Thus, MALT1 S562 phosphorylation was also present
after CBM-complex disassembly that resulted from BCL10
degradation. In contrast, S649 and S803 phosphorylation
rapidly declined after only 30–60 min of stimulation. The
data suggested that MALT1 phosphorylation may be involved
in CBM downstream effects rather than initial CBM complex
assembly.
To test what fraction of MALT1 is phosphorylated in acti-
vated T cell, we performed ST-PD of CARD11 KO Jurkat
T cells reconstituted with CARD11-FS (Seeholzer et al.,
2018). Migration of CARD11-associated MALT1 was severely
shifted, which is caused by the multiple mono- and poly-ubiq-
uitinations of CBM-bound MALT1 after T cell stimulation
(Figure 2C). In addition, MALT1 S562 and S649 phosphoryla-
tions were detected in the CARD11-bound fraction, and phos-
phorylation was maximal 20 min after P/I treatment. To
determine whether proteolytically active MALT1 is phosphory-
lated, we used the biotin-labeled MALT1 activity-based probe
(ABP), which attaches covalently to active MALT1 after stimu-
lation (Eitelhuber et al., 2015). MALT1 ABP precipitated a
slower-migrating MALT1 only after P/I stimulation, suggesting
that active MALT1 is highly modified, which precisely corre-
lates with the early appearance of mono- and poly-ubiquiti-
nated MALT1 species after 5 min of stimulation (Figure 2D).
Indeed, active ABP-coupled MALT1 was also phosphorylated
at S562 and S649, and again, MALT1 phosphorylation on both
residues was delayed and was first visible after 10 min of P/I
treatment, a time point at which MALT1 was already active.
As noted earlier, although MALT1 S649 phosphorylation was
transient, MALT1 S562 phosphorylation persisted during later
time points of MALT1 protease activity. We also monitored
MALT1 substrate cleavage and detected CYLD, HOIL-1, and
Regnase-1 cleavage from shortly after MALT1 activation and
persisting throughout the stimulation time course. Thus,
MALT1 phosphorylation takes place within the CBM complex
on ubiquitinated and proteolytic active MALT1.876 Cell Reports 29, 873–888, October 22, 2019CBM Complex Associated CK1a Can Act as a MALT1
Kinase
Previous data have demonstrated that the protein kinase CK1a
interacts with CARD11 to regulate the CBM complex upon
T cell stimulation (Bide`re et al., 2009). CK1a phosphorylates
at ‘‘non-primed’’ sites containing acidic residues in the 3 po-
sition or at ‘‘primed’’ sites in which a preceding phosphorylation
triggers CK1a recognition (Venerando et al., 2014). Protein
kinase predictions suggest that S562 and S645 in human
MALT1B may be putative primed and non-primed substrate
sites for CK1a, respectively (Figure 3A). As suggested earlier,
CK1a binds to CARD11, MALT1, and BCL10 in Jurkat T cells
after P/I stimulation (Figure 3B). To clarify which CBM complex
members are responsible for CK1a binding, we determined
the association in CARD11, BCL10, and MALT1 KO Jurkat
T cells. Absence of any CBM subunit abrogates a complex for-
mation, as evident after BCL10-IP (Figure S2A). In line with the
proposed direct recruitment of CK1a to CARD11 (Bide`re et al.,
2009), lack of CARD11 abolished CK1a binding to BCL10 and
MALT1 (Figure 3B). However, residual, but severely reduced,
CK1a-CARD11 interaction was detectable in BCL10 or
MALT1 KO cells, suggesting that both proteins contribute
directly or indirectly to efficient integration of CK1a into the
CBM complex. Next, we determined whether the CK1a-bound
CBM complex contained the MALT1 phosphorylations (Fig-
ure 3C). A time-course analysis revealed that CK1a is recruited
to CARD11 and MALT1 within 2 min of P/I stimulation. MALT1
S562 and S649 phosphorylations were detected 10 min after
stimulation in the CK1a-bound CBM complex, demonstrating
that CK1a co-localizes with phosphorylated MALT1 after
T cell stimulation.
To investigate the contribution of BCL10-MALT1 to the CK1a-
CARD11 interaction in more detail, we expressed CK1a-FS and
hemagglutinin (HA)-CARD11 alone or together with FLAG-
MALT1 and FLAG-BCL10 in HEK293 cells lacking endogenous
CARD11 (Figure 3D). Binding of CARD11 to CK1a was
augmented in the presence of BCL10 and MALT1, suggesting
that the CBM holo-complex constitutes the optimal platform
for CK1a recruitment. Moreover, we assessed the association
of CK1a-FS to HA-MALT1 (Figure 3E). Although MALT1 did not
bind to CK1a in the absence of BCL10, CK1a associated with
BCL10-MALT1 complexes in the absence of CARD11, and that
interaction was not further augmented by CARD11 co-expres-
sion or CBM complex formation in HEK293 cells. To verify
CARD11-independent interaction of CK1a with BCL10-MALT1
in Jurkat T cells, we expressed HA-MALT1, FLAG-BCL10,
and FLAG-CK1a in CARD11 KO Jurkat T cells (Figure 3F).
Again, HA-MALT1 alone was unable to bind to CK1a, but
BCL10/MALT1 associated with CK1a, even in the absence
of CARD11, implicating BCL10-MALT1 in conferring an addi-
tional binding surface for the recruitment of CK1a to the CBM
complex.
To address whether CK1a can phosphorylate MALT1 at
the identified site S562 for which we have generated a highly
selective phospho-antibody, we performed in vitro kinase as-
says with recombinant-purified glutathione S-transferase
(GST)-MALT1 (aa 325–760) as well as hexa-histidine tag
(6xHis)-MALT1-GyrB-HA (aa 334–813) covering the entire C
Figure 2. T Cell Stimulation Triggers MALT1 Phosphorylation within the Active CBM Complex
(A and B) Kinetics of MALT1 phosphorylation in Jurkat T cells after CD3/CD28 (A) and P/I (B) stimulation. MALT1 phosphorylation was determined after MALT1-IP
(for S562 and S649) or anti-pS803-IP. In parallel, CARD11 S645 phosphorylation, CBM complex formation (BCL10-IP), and IkBa phosphorylation/degradation
were determined.
(C) CARD11 association of MALT1 phosphorylated on S562 and S649 after P/I stimulation was detected in CARD11 KO Jurkat T cells reconstituted with CARD11
WT-FS after ST-PD of CARD11.
(D) S562 and S649 phosphorylation of protease active, ubiquitinated MALT1 was detected after MALT1-ABP-PD. In parallel, MALT1 substrate cleavage was
detected by WB.terminus (Figures 3G and S2B). After in vitro kinase reactions,
recombinant CK1a was able to phosphorylate GST-MALT1
325–760 and His-MALT1 334–813 at serine 562 within theconsensus sequence. Thus, CK1a binds to BCL10/MALT1, as-
sociates with p-MALT1 in the CBM complex, and can catalyze
in vitro phosphorylation on MALT1 at serine 562.Cell Reports 29, 873–888, October 22, 2019 877
Figure 3. CK1a Is Recruited to the CBM Holo-Complex and Phosphorylates MALT1 at Serine 562
(A) Consensus sequence of primed canonical or non-primed canonical CK1a phospho-acceptor sites. Potential primed and non-primed CK1a phosphorylation
sites in human MALT1 are indicated.
(B) Binding of CK1a to CARD11, MALT1, and BCL10 in parental and respective KO Jurkat T cells after P/I stimulation was determined after CK1a-IP. See also
Figure S2A.
(C) Kinetics of CK1a association to MALT1 phosphorylated on S562 and S649 was determined by phospho-specific antibodies after CK1a-IP.
(D) Binding of HA-CARD11 to CK1a-FS in the absence or presence of 3xFLAG-BCL10 and 3xFLAG-MALT1 in HEK293 cells.
(E) Association between HA-MALT1 and 3xFLAG-CK1a, either alone or in the presence of only 3xFLAG-BCL10 or 3xFLAG-BCL10 and CARD11-FS in HEK293
cells.
(F) Interaction between HA-MALT1 and 3xFLAG-CK1a, either alone or in the presence of 3xFLAG-BCL10 in CARD11 KO Jurkat T cells.
(G) In vitro CK1a kinase assay on bacterial GST-MALT1 (aa 325–760) was followed by detection of MALT1 pS562 by WB. See also Figure S2B.CK1a Activity Triggers CBM Complex Assembly and
Downstream Signaling
CK1a exerts positive and negative regulatory effects on CBM
complex signaling (Bide`re et al., 2009). To dissect the role of
CK1a for CBM assembly and downstream function, we gener-
ated CK1a KO Jurkat T cells by using a single-guide RNA
(sgRNA) targeting exon3 (Figure S3A). Two independent Jurkat
T cell clones were obtained, which had lost CK1a protein
expression because of destructive frameshift mutations in
exon 3 (Figures 4A and S3B). CK1a KO Jurkat T cells were viable
and did not exhibit defects in cell growth. To prove that cellular
effects are caused by CK1a KO, we rescued CK1a KO Jurkat
T cell clone 6 with CK1a WT, kinase-dead D136N or CARD11-
binding mutant Y292A (Bide`re et al., 2009). CK1a constructs
were homogenously transduced and expressed in CK1a KO
Jurkat T cells, and the slightly altered migration of CK1a878 Cell Reports 29, 873–888, October 22, 2019D136N was due to conformational changes and was not on the
level of the mRNA, as revealed by PCR and sequencing (Figures
4B, S3C, and S3D).
We assessed the effects of CK1a deficiency on CBM down-
stream signaling in response to T cell stimulation. Indeed,
CK1a deficiency abolished NF-kB signaling and MALT1 prote-
ase activation, as evident from loss of IkBa phosphorylation/
degradation, NF-kB DNA binding, and MALT1-catalyzed CYLD
or HOIL-1 cleavage after anti-CD3/CD28 or P/I stimulation
(Figures 4C and S3E). Extracellular signal-regulated kinase
(ERK) phosphorylation and protein kinase C theta (PKCq)-
dependent phosphorylation of CARD11 on S645 were normal
in CK1a KO cells, ruling out defective upstream signaling. More-
over, loss of CK1a did not affect NF-kB signaling in response to
tumor necrosis factor alpha (TNF-a) stimulation (Figure S3F).
Reconstitution with CK1a WT, but not inactive CK1a D136N,
Figure 4. CK1a Kinase Activity and CARD11 Binding Trigger CBM Complex Formation, NF-kB Activation, and MALT1 Phosphorylation
(A) Generation of CK1a KO Jurkat T cells by CRISPR/Cas9. Loss of CK1a was verified by WB. See also Figures S3A and S3B.
(B) Protein expression of CK1a WT, D136N, and Y292A in reconstituted CK1a KO Jurkat T cells was analyzed by WB. See also Figures S3C and S3D.
(C) NF-kB signaling in CK1aKO Jurkat T cells in response toCD3/CD28 stimulation was analyzed by electrophoretic mobility shift assay (EMSA) andWB. See also
Figures S3E and S3F.
(D) Effects of CK1a D136N and Y292A mutants on NF-kB signaling and MALT1 activation after CD3/CD28 stimulation was assessed by EMSA andWB. See also
Figure S3G. Unspecific bands are marked with asterisk.
(E) Requirement of CK1a activity and CARD11 binding for CBM complex formation was monitored by BCL10-IP and WB in Jurkat T cells expressing CK1a,
D136N, and Y292A mutants. See also Figure S3H.
(F) CK1a recruitment to CARD11, BCL10, and MALT1 was determined by CK1a-IP and WB in CK1a KO Jurkat T cells reconstituted with CK1a WT, D136N, or
Y292A mutant.
(G) Analyses of MALT1 phosphorylation on S562, S649, and S803 in Jurkat T cells expressing CK1a WT, D136N, or Y292A. See also Figure S3I.
(H) NF-kB reporter assay after transfection of CARD11 WT or L225LI mutant in CK1a-deficient Jurkat T cells reconstituted with mock, CK1a WT, or D136N
mutant. Fold changes in constitutive induction of the NF-kB reporter gene are depicted.
The data represent means ± SD of six biological replicates. *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001. See also Figure S4.
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restored NF-kB signaling and MALT1 protease activation upon
T cell stimulation (Figures 4D and S3G). In line with defective
signaling, inducible CBM assembly was lost in CK1a-deficient
Jurkat T cells and was rescued by the transduction of CK1a
WT but not the D136N mutants (Figures 4E and S3H). Further,
defective CARD11 recruitment by the CK1a-mutant Y292A
severely impaired NF-kB and MALT1 activation as well as
CBM complex formation (Figures 4D, 4E, and S3G). Importantly,
neither CK1a Y292A nor CK1aD136Nwas efficiently recruited to
CARD11, BCL10, and MALT1 after P/I stimulation, suggesting
that the CK1a-CARD11 interaction, as well as the CK1a catalytic
activity, is required for assembly of the CK1a-containing CBM
complex (Figure 4F). Using phospho-specific MALT1 antibodies,
we found that MALT1 phosphorylation on the three serine resi-
dues 562, 649, and 803 was lost in the absence of CK1a (Figures
4G and S3I). Again, although CK1a WT could rescue MALT1
phosphorylation, MALT1 phosphorylation on all three serines
was strongly diminished in the CARD11-binding-defective
CK1a Y292A and absent in the kinase-dead CK1a D136N (Fig-
ure 4G). Thus, CK1a catalytic activity is essential to initiate
CBM complex assembly, which subsequently drives MALT1
protease activation, MALT1 phosphorylation, and downstream
signaling.
It has been suggested that CK1a kinase activity also exerts a
negative role in counteracting CBM-triggered T cell activation by
phosphorylating S608 in the linker region of CARD11 (Bide`re
et al., 2009). Indeed, expression of CARD11 S608A in
CARD11-deficient JPM50.6 cells was more effective in rescuing
NF-kB activation when compared with CARD11 WT, confirming
the negative regulatory effect of CK1a in the CBM complex (Fig-
ures S4A–S4C). Nevertheless, reconstitution of CK1a KO Jurkat
T cells underscores the dominant function of CK1a catalytic ac-
tivity as driving CBM complex formation.
Because CK1a catalytic activity is essential for CBM complex
formation, reconstitution experiments are unable to prove
whether CK1a directly catalyzes MALT1 phosphorylation in acti-
vated T cells. Nevertheless, to address whether CK1a kinase
activity exercises a catalytic function downstream of CARD11
in the assembled CBM complex, we took advantage of the
oncogenic CARD11 L225LI variant, which bypasses the up-
stream necessity for CK1a by promoting constitutive CBM com-
plex assembly (Lenz et al., 2008). CK1a constitutively associates
with the CARD11 L225LI-containing CBM complex in theFigure 5. C-Terminal MALT1 Phosphorylation Augments NF-kB Signal
(A) Induction of NF-kB-EGFP reporter in parental and MALT1 KO Jurkat T cells a
(B) Quantification of NF-kB activation by counting of EGFP-positive cells, see (A),
SD of four biological replicates. ****p% 0.0001.
(C) Equivalent transduction of MALT1 constructs in MALT1 KO;NF-kB-EGFP rep
(D) Protein expression of transduced MALT1 WT and mutants, see (C), was anal
(E) Number of EGFP-positive cells was determined in MALT1BWT (black), MALT1
course of P/I and CD3/CD28 stimulation by FACS.
(F) Quantification of NF-kB activation by EGFP-positive cells in MALT1 KO;NF-kB
5 h of CD3/CD28, P/I, or TNF-a stimulation. The data represent means ± SD of fi
(G and H) Effects of combinatory MALT1B 6xS/A mutant on IkBa, JNK, and ERK
Figures S5, S6A, and S6B.
(I) Effects of MALT1B 6xS/A mutant on NF-kB activation after P/I or CD3/CD28 s
(J)MALT1 substrate cleavage of CYLD andHOIL-1was determined inMALT1BWT
Figure S6F.absence of upstream signaling input (Bognar et al., 2016; Knies
et al., 2015). As expected, oncogenic CARD11 L225LI more
potently induced NF-kB reporter gene induction than CARD11
WT in unstimulated CK1a WT-expressing Jurkat T cells (Fig-
ure 4H). However, constitutive NF-kB induction by CARD11
L225LI was strongly reduced in mock or kinase-dead CK1a
D136N reconstituted CK1a KO Jurkat T cells, demonstrating
that downstream signaling of oncogenic CARD11 is also medi-
ated by CK1a kinase activity. As expected, NF-kB activation
after P/I or CD3/CD28 stimulation in CARD11 WT and CARD11
L225LI-expressing cells was also strongly diminished in the
absence of CK1a activity. Thus, NF-kB activation by a constitu-
tively assembled CBM complex still relies on CK1a activity,
strongly arguing for an additional, kinase-dependent down-
stream function of CK1a in TCR/CD28 signaling.
MALT1 Phosphorylation Augments Canonical NF-kB
Signaling and T Cell Activation
To determine the contribution of MALT1 phosphorylations for
NF-kB activation, we transduced a viral NF-kB-EGFP reporter,
consisting of EGFP under the control of six NF-kB sites, into
parental or MALT1 KO Jurkat T cells. NF-kB transcriptional
activation was measured by determining EGFP-positive Jurkat
T cells using fluorescence-activated cell sorting (FACS) (Fig-
ure 5A). Although NF-kB was induced after P/I, CD3/CD28, or
TNF-a stimulation in parental Jurkat T cells, absence of MALT1
abolished EGFP expression in response to P/I or CD3/CD28,
but not TNF-a (Figure 5B). We transducedMALT1BWT, pairwise
MALT1B phospho-defective mutants (S559/562A, S645/649A,
and S803/805A), MALT1B lacking all six phospho-acceptor
serines (MALT1B 6xS/A), and the putative phospho-mimetic
MALT1B (MALT1B 6xS/D) into MALT1 KO;NF-kB-EGFP Jurkat
T cells (Figure 5C). All MALT1B constructs were expressed at
equivalent levels (Figure 5D). We performed a kinetic analysis
measuring the number of EGFP-positive Jurkat T cells after
CD3/CD28 or P/I stimulation, and decreased expression of the
NF-kB-EGFP reporter was seen at all times between 2 and 6 h
of stimulation in MALT1B 6xS/A and 6xS/D compared with the
WT (Figure 5E). Quantification of EGFP expression after 5 h of
stimulation revealed that combined mutation of all phospho-
sites in MALT1B 6xS/A and the double-mutant MALT1B S803/
805A were significantly impairing NF-kB activation in response
to P/I or CD3/CD28 (Figure 5F). Decreased NF-kB activationing and Activation in Jurkat T Cells
s determined by FACS after P/I, anti-CD3/CD28, or TNF-a stimulation.
after P/I, anti-CD3/CD28, and TNF-a stimulation. The data represent means ±
orter Jurkat T cells was monitored by the surface-marker hDCD2 in FACS.
yzed by WB.
B 6xS/A (blue), and MALT1B 6xS/D (red) expressing Jurkat T cells after a time
-EGFP reporter cells reconstituted with MALT1BWT or phospho-mutants after
ve biological replicates. *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001.
after CD3/CD28 (G) or P/I (H) stimulation were investigated by WB. See also
timulation was investigated by EMSA. See also Figures S6C–S6E.
and 6xS/Amutant cells in response to CD3/CD28 and P/I stimulation. See also
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for MALT1B S559/562A was only significant after CD3/CD28
stimulation, whereas MALT1B S645/649A did not show signifi-
cant effects. MALT1B 6xS/Dwas unable to rescue NF-kBactiva-
tion and thus also acted as a phospho-defective, instead of a
phospho-mimetic, mutant. However, replacing a serine with
negatively charged aspartic or glutamic acid is often insufficient
for acquiring a phospho-mimetic variant, which, for instance, is
also observed in the case of IkBa, where these putative phos-
pho-mimetic residues rendered the NF-kB inhibitor degradation
resistant, just like the phospho-defective serine to alanine
mutant (Traenckner et al., 1995; Brockman et al., 1995).
MALT1-independent NF-kB activation in response to TNF-a
was unchanged by the MALT1 phospho-mutations (Figure 5F).
Thus, MALT1 phosphorylation sites are required for optimal in-
duction of NF-kB transcriptional responses and C-terminal
MALT1 phosphorylations exert combinatorial effects on TCR/
CD28-induced NF-kB activation in Jurkat T cells.
Rescue by the pairwise MALT1 phospho-defective mutants
S559/562A, S645/649A, and S803/805A in MALT1 KO Jurkat
T cells led to aweak, but consistent, reduction in NF-kB signaling
and activation after CD3/CD28 or P/I stimulation, whereas TNF-
a-driven NF-kB activation was not altered (Figures S5A–S5E).
Because we observed combinatorial effects of the phospho-
site mutations, we focused on analyzing the biochemical effects
of the MALT1 6xS/A and 6xS/D mutants. In line with the
decreased NF-kB reporter-gene activation, P/I- and CD3/
CD28-induced IkBa phosphorylation and degradation were
impaired in Jurkat T cells expressing MALT1B 6xS/A (Figures
5G and 5H), leading to severely diminished NF-kB DNA binding
(Figure 5I). In addition, JNK phosphorylation was diminished in
the MALT1B phospho-defective mutant 6xS/A, whereas
MALT1-independent ERK activation or NF-kB signaling in
response to TNF-a was unaffected (Figures 5G, 5H, and S6A).
Similarly, NF-kB and JNK activation was impeded by expression
of MALT1B 6xS/D, confirming that the exchange to aspartic acid
resulted in a defective, instead of mimetic, MALT1 variant (Fig-
ures S6B and S6C). As expected, C-terminal MALT1 phospho-
defective 6xS/A mutations did not interfere with the CBM com-
plex assembly after P/I stimulation (Figure S6D). In addition,
MALT1 ubiquitination was not affected in the phospho-defective
mutant MALT1B 6xS/A after P/I stimulation, ruling out MALT1
poly-ubiquitination being controlled by phosphorylation (Figures
S6D and S6E). MALT1 protease activity and cleavage of CYLD
and HOIL-1 by phospho-defective MALT1B 6xS/A was induced
in response to T cell stimulation, but slightly less efficiently than
MALT1B WT (Figures 5J and S6F). Thus, C-terminal MALT1
phosphorylation is required to couple the CBM complex to
optimal downstream signaling.
To corroborate the necessity of MALT1 phosphorylation for
activation of primary T cells, we used retroviral transduction to
rescue CD4 T cells from MALT1-deficient mice with human
MALT1B constructs. Infected CD4 T cells were identified by
co-expression of the surface marker Thy1.1, and equivalent
expression of MALT1B WT and phospho-mutant proteins was
verified by western blot of the sorted cells (Figures 6A and
S7A). To determine NF-kB transcriptional responses in primary
T cells, we measured induction of NF-kB-regulated genes IL-2,
TNFAIP3/A20, and NFKBIA/IkBa in reconstituted MALT1/882 Cell Reports 29, 873–888, October 22, 2019CD4 T cells after CD3/CD28 stimulation by RT-PCR. The genes
were strongly induced in aMALT1-dependentmanner after 1–4 h
of TCR/CD28 stimulation (Figures 6B and S7B). Similar to what
was found for NF-kB reporter activation in Jurkat T cells, phos-
pho-defective MALT1B mutants were impaired in upregulating
the target genes, and again, the combined mutation of all six
phosphorylation sites in 6xS/A most severely affected the induc-
tion of all three genes (Figures 6B and S7B).
We used single-cell FACS to investigate the effects of MALT1
phospho-mutants on NF-kB signaling and IL-2 protein expres-
sion in CD4 T cells. P/I stimulation for 20 min did not induce
IkBa degradation in untransduced MALT1-deficient, Thy1.1-
negative or mock-infected, Thy1.1-positive CD4 T cells (Figures
7C and S7C). In contrast, reconstitution of MALT1B WT rescued
stimulus-dependent IkBa degradation (Figure 6C). IkBa degra-
dation was still detectable in the MALT1B phospho-defective
mutants S559/562A, S645/649A, and S803/805A, but was
significantly less pronounced than in MALT1B WT (Figures 6C
and 6D). Combinedmutation of all six serine residues in MALT1B
6xS/Amost severely attenuated IkBa degradation in CD4 T cells.
Furthermore, wemeasured intracellular IL-2 expression by FACS
in reconstituted CD4 T cells after anti-CD3/CD28 or P/I stimula-
tion to confirm that defective MALT1 phosphorylation prevents
optimal T cell activation (Figures 6E–6H). Although expression
of MALT1B WT rescued induction of IL-2 in MALT1/ CD4
T cells, upregulation of IL-2 was significantly impaired in the
phospho-defective mutants, and the strongest effects were
observed by mutating all phospho-sites in MALT1B 6xS/A.
Taken together, MALT1 phosphorylation in the C terminus
channels the CBM complex to canonical NF-kB signaling and
gene induction in Jurkat and CD4 T cells after TCR/CD28
co-stimulation.
Phosphorylation of the MALT1 C Terminus Contributes
to Survival Signaling in ABC-DLBCL Cells
As part of the CBM complex, MALT1 is essential for controlling
NF-kB survival signaling in ABC-DLBCL cells (Ngo et al., 2006).
We, therefore, tested whether MALT1 is prone to chronic phos-
phorylation in ABC-DLBCL cell lines by using anti-pS562-
MALT1, the antibody that most effectively and selectively recog-
nizes phosphorylated MALT1 in human cells (see Figure 2). After
MALT1-IP, we detected phosphorylation of MALT1 on S562 in all
four ABC-DLBCL cell lines (HBL1, TMD8, OCI-Ly3, and U2932)
even in the absence of stimulation (Figure 7A). We did not detect
constitutive MALT1 phosphorylation on S562 in the germinal
center B cell-like (GCB) DLBCL cell lines BJAB, SUDHL4, and
SUDHL6, but phosphorylation in SUDHL4 and SUDHL6 was
induced by P/I stimulation (Figure 7B). To determine whether
MALT1 phosphorylation in HBL1 and TMD8 cells, carrying up-
stream mutations in the BCR-adaptor CD79B, relies on up-
stream signaling, we treated those cells with Bruton tyrosine ki-
nase (BTK) inhibitor ibrutinib (Figure 7C). Phosphorylation of
MALT1 was sensitive to BTK inhibitor treatment, revealing that
it is dependent on chronic upstream BCR signaling. In contrast,
MALT1 phosphorylation in OCI-Ly3 cells, carrying an oncogenic
variant of CARD11, was more resistant to ibrutinib treatment
than the HBL1 and TMD8 cells were (Figure 7C). Furthermore,
expression of oncogenic CARD11 L225LI in HBL1 cells, which
Figure 6. MALT1 Phosphorylation Enhances NF-kB Signaling and IL-2 Expression in CD T Cells
(A) Expression of MALT1 WT and S/A mutants was analyzed by WB. See also Figure S7A.
(B) Analyses of induction of IL-2, TNF-AIP3/A20, and NFKBIA/IkBa in MALT1 KO CD4 T cells reconstituted with MALT1B WT or phospho-defective S/A mutants
after CD3/CD28 stimulation. Transcript levels were normalized to mRNA levels of b-actin. The data represent means ± SD of four biological replicates. *p < 0.05,
**p < 0.01, ***p% 0.001, ****p < 0.0001. See also Figure S7B.
(C and D) Single-cell analyses of IkBa protein levels before and after P/I stimulation were analyzed in MALT1B WT and S/A mutant reconstituted CD4 T cells by
intracellular staining and FACS (C). Median fluorescence intensity (MFI) of IkBa-fluorescein isothiocyanate (FITC) was quantified, and induction of IkBa
degradation was determined by forming the difference inMFI of unstimulated to stimulated cells. Relative IkBa degradation betweenMALT1BWT andS/Amutant
cells was compared and statistically analyzed (D). The data represent means ± SD of six biological replicates. *p < 0.05, **p < 0.01, ****p < 0.0001. See also
Figure S7C.
(E–H) Single-cell analyses of IL-2 production before and after CD3/CD28 (E and F) or P/I (G and H) stimulation was analyzed in MALT1B WT and S/A mutant-
reconstituted CD4 T cells by intracellular staining and FACS (E and G). IL-2 induction was determined by the percentage of IL-2-expressing cells in unstimulated
and stimulated cells. Relative IL-2 induction between MALT1BWT and S/A mutant cells was compared and analyzed statistically (F and H). *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
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Figure 7. Phosphorylation in the MALT1 C Terminus Contributes to Survival Signaling in ABC-DLBCL Cells
(A) MALT1B S562 phosphorylation was determined after MALT1-IP and WB in four ABC and three GCB DLBCL cell lines, as depicted.
(B) MALT1B S562 phosphorylation was determined after MALT1-IP and WB, following P/I stimulation in GCB DLBCL cell lines SUDHL4 and SUDHL6.
(C) ABC-DLBCL cells HBL1, TMD8, and OCI-Ly3 were treated with the BTK inhibitor ibrutinib (20 nM, 18 h), and MALT1B S562 phosphorylation was assessed
after MALT1-IP and WB.
(D) ABC-DLBCL cell line HBL1, transduced with mock, CARD11 WT, or CARD11 L225LI, was treated with the BTK inhibitor ibrutinib (20 nM, 18 h), and MALT1B
S562 phosphorylation was assessed after MALT1-IP and WB.
(E) Knockdown of endogenous MALT1 in rescue experiments was determined by WB 2 days after transduction of shRNA in HBL1, TMD8, and OCI-Ly10 cells.
(F) HBL1, TMD8, and OCI-Ly10 were transduced with MALT1 shRNA and then infected with mock, MALT1B WT, or mutant constructs. EGFP-positive cells in
mock, MALT1WT, andmutants at days 2–10 after transduction weremeasured. Time series depict ratios of cells expressing GFP compared with the subset of all
living cells, normalized to day 2. Error bars depict SEMs (±SEM) over four biological replicates for each time point and vector. Statistical analyses was performed
as described in Method Details; p values are given for one-tailed growth comparisons over all time points for S/A mutant cells versus MALT1B WT cells.reduces ibrutinib toxicity (Nagel et al., 2015), impaired the
decrease of MALT1 S562 phosphorylation in response to BTK
inhibition (Figure 7D). Thus, the constitutive CBM complex as-
sembly, as a result of chronic BCR signaling or oncogenic
CARD11 mutations, induces S562 phosphorylation of MALT1
in ABC-DLBCL cells.884 Cell Reports 29, 873–888, October 22, 2019MALT1 silencing induces toxicity to ABC-DLBCL cells
(Ngo et al., 2006). To assess the functional consequences of
constitutive C-terminal MALT1 phosphorylation in ABC-DLBCL
cells, we downregulated endogenous MALT1 by retroviral short
hairpin RNA (shRNA) knock down in the ABC-DLBCL cell lines
HBL1, OCI-Ly10, and TMD8 (Figure 7E). Subsequently, cells
were reconstituted with MALT1B WT or the MALT1B phospho-
defective mutants S559/562A, S645/649A, S803/805A, or com-
bined 6xS/A. EGFP served as a marker to follow the fate of the
transduced tumor cells (Figure 7F). As expected, silencing of
MALT1 led to growth arrest in all ABC-DLBCL cell lines, which
was restored upon ectopic expression of MALT1B WT. The
MALT1B phospho-mutant S559/562A and S645/649A did not
significantly affect cell growth of ABC-DLBCL cells. However,
the MALT1 S803/805A mutant, as well as the combined
MALT1 6xS/A, significantly impaired the ability of MALT1 to
rescue growth of the three ABC-DLBCL cell lines (Figure 7F).
Thus, phosphorylation at the C terminus of MALT1 exerts a
positive role that is essential for the survival of BCR-addicted
ABC-DLBCL cells.
DISCUSSION
In an unbiased mass spectrometry approach, we have identified
several C-terminal phosphorylation sites on MALT1 in activated
Jurkat T cells. MALT1 is prone to multiple covalent modifications
upon acute TCR/CD28 co-stimulation in T lymphocytes or
chronic BCR signaling in ABC-DLBCL cells (Bide`re et al., 2009;
Ferch et al., 2009; Oeckinghaus et al., 2007), and so far,
MALT1 modifications have been primarily attributed to regulato-
ry K63-linked poly-ubiquitination on multiple C-terminal lysines
and mono-ubiquitination on K644 in MALT1A, driving NF-kB
and MALT1 protease activation, respectively (D€uwel et al.,
2009; Oeckinghaus et al., 2007; Pelzer et al., 2013). To these
ubiquitin-linkages, we now add stimulus-dependent phosphory-
lation as a regulatory process that controls MALT1 function. By a
MALT1-directedMSapproachwe identified six C-terminal phos-
phorylation sites in activated T cells; of which, two sites (S649
and S803) have also been found in a global phospho-proteome
approach after IgM-crosslinking in a murine B cell line (Satpathy
et al., 2015), indicating comparable regulation in T and B cells.
Interestingly, MALT1 modifications are confined to the flexible
C terminus, which protrudes from the densely packed BCL10/
MALT1 core filaments that are connected by a CARD-DD inter-
face (Schlauderer et al., 2018). Thus, the MALT1 C terminus, en-
compassing the paracaspase domain, Ig3 domain, and TRAF6
binding motifs represents the ‘‘outer’’ surface of the CBM com-
plex, which is responsible for connecting to various downstream
signaling mediators and MALT1 substrates. In line with that, a
highly dynamicmodification network involving poly-/mono-ubiq-
uitination and phosphorylation controls MALT1 scaffolding and
protease activity upon T cell stimulation.
MALT1 is phosphorylated with similar kinetics at S562, S649,
and S803 after T cell stimulation, suggesting that they may act
in a concerted manner in augmenting NF-kB signaling. Indeed,
co-immunoprecipitations studies reveal that pS562 and pS649
are detected on activeMALT1within the CBM complex, suggest-
ing that not the majority of MALT1 is prone to phosphorylation,
but only the fraction engaged in signaling. Similarly, although
mutation of all six phospho-acceptor sites caused the strongest
effects on NF-kB activation, pairwise mutations were not as se-
vere. However, in addition, the pairwise MALT1B mutants pro-
vided a consistent picture because the strongest effects were
observed with the very C-terminal mutation S803/805A, whereasS559/562A or S645/659A displayedmilder or no effects onNF-kB
activation, respectively. The combined action of MALT1 phos-
phorylation also indicates that the lack of serine 562 in rodents
may not have a detrimental effect on signal propagation. In gen-
eral, weaker CD3/CD28 induction more severely relied on intact
phosphorylation sites compared with strong P/I stimulation, sug-
gesting that MALT1 phosphorylation may facilitate conversion of
a weak antigen-receptor stimulus into a robust T cell response.
Interestingly, the viability of NF-kB-addicted ABC-DLBCL lym-
phoma cells also relies on MALT1 phosphorylation, and again,
the 6xS/A or the most C-terminal S803/805A caused the stron-
gest effects on MALT1-dependent ABC-DLBCL cell survival.
The identification of MALT1 phosphorylation represents a step
forward in the understanding how the multi-protein CARD11-
BCL10-MALT1 complex controls signaling in physiological and
pathological settings (Phelan et al., 2018; Qiao et al., 2013).
We have been able to identify CK1a as a protein kinase that
can bind to BCL10-MALT1 and at least in vitro directly phosphor-
ylate MALT1 on S562. We confirmed the association of CK1a
with the CBM complex and demonstrated that it functions as a
negative regulator in TCR-induced NF-kB activation by phos-
phorylating the putative CK1a phospho-acceptor S608 in
CARD11 (Bide`re et al., 2009). However, by reconstituting CK1a
KO Jurkat T cells, we clearly demonstrate that the main role of
CK1a kinase activity is to foster CBM formation and, thus, to pro-
mote T cell activation. Initial CARD11 linker phosphorylation at
S645 catalyzed by PKCq is unchanged in the absence of
CK1a, indicating that CK1a is not involved in upstream events
(Shinohara et al., 2007; Sommer et al., 2005). Notably, in the
case of WNT signaling, CK1a functions as a primed kinase that
catalyzes the hierarchical multi-site phosphorylation of the
adenomatous polyposis coli (APC) protein after initial GSK3b
phosphorylation. In contrast, CK1a can act as a priming kinase
for GSK3b on b-catenin (Cesaro and Pinna, 2015; Cruciat,
2014). GSK3b was also found to associate with the CBM com-
plex and to promote NF-kB signaling in T and B cells (Abd-Ellah
et al., 2018; Bognar et al., 2016). It is tempting to speculate
that, after the initial priming phosphorylation in CARD11 by
PKCq or other potential initiator kinases, CK1a contributes to
CARD11 hyper-phosphorylation and thereby induces the
conformational changes that provide accessibility of the
CARD-domain for BCL10-MALT recruitment (Chan et al.,
2013). Such positive feedback of CK1a with other protein ki-
nases on the level of CARD11 could also support the reported
switch-like mechanism for IKK/NF-kB activation by the CBM
signaling complex (Shinohara et al., 2014). Importantly, CK1a
also exerts a positive effect in the context of oncogenic
CARD11 L225LI that assembles independently from upstream
signaling, indicating that CK1a also regulates CARD11 down-
stream events. MALT1 is not phosphorylated on serines 562,
645, and 803 in CK1a kinase dead cells, but the concomitant
loss of CBM complex formation precludes a demonstration of
CK1a as a direct MALT1 kinase in T cells. Moreover, despite
the fact that CK1a can phosphorylate S562 in vitro, it is unlikely
that it directly catalyzes all phosphorylations in the MALT1 C
terminus. Nevertheless, as with CARD11 hyper-phosphoryla-
tion, it is possible that CK1a is either primed by initial phosphor-
ylation or alternatively, primes phosphorylation by other proteinCell Reports 29, 873–888, October 22, 2019 885
kinases to induce switch-like activation of MALT1 downstream
signaling.
MALT1 phosphorylation takes place within the assembled
CBM complex on ubiquitin-modified MALT1, implying that ubiq-
uitination precedes phosphorylation. Active MALT1 is ubiquiti-
nated and phosphorylated, but in contrast to mutation of the
mono-ubiquitin acceptor site K644 in MALT1A, MALT1 protease
activation and substrate cleavage is not severely altered in the
phospho-defective mutants (Pelzer et al., 2013). Phosphoryla-
tions may have some effects on the conformational rearrange-
ments in the MALT1 Ig3 domain that are required to activate
MALT1 protease (Wiesmann et al., 2012), but MALT1 phosphor-
ylation primarily controls MALT1 scaffolding function and
optimal NF-kB and JNK signaling in activated T cells. The exact
mechanisms needs to be resolved, but it seems likely that
MALT1 C-terminal phosphorylations induce conformational
changes that promote downstream signaling, e.g., by facilitating
the recruitment of additional factors. It has been suggested that
IkBa directly associates with MALT1 after TCR/CD28 co-ligation
in a CK1a-dependent manner (Carvalho et al., 2010), suggesting
that coordinated recruitment of the IKK and IkBa/NF-kB com-
plexes promotes efficient activation of canonical NF-kB
signaling. Different modifications on MALT1 may cooperate in
driving optimal NF-kB activation, which may allow for an ‘‘all-
or-nothing’’ activation above and prevent a potentially harmful
activation below a certain signaling threshold. With the available
tools, we have not been able to detect a potentially very transient
CBM holo-complex that contains NEMO/IKKb as well as IkBa/
NF-kB, but future structural work elucidating the periphery of
the BCL10-MALT1 filaments will certainly help to unravel how
ubiquitination and phosphorylation cooperate in the regulation
of CBM downstream signaling.STAR+METHODS
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Daniel
Krappmann (daniel.krappmann@helmholtz-muenchen.de). All reagents developed for this study are available under Material Trans-
fer Agreements from Helmholtz Zentrum M€unchen.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Cell culture
Adherent HEK293, HEK293T and Phoenix cells were cultured in DMEM supplemented with 10% FCS and 100 U/ml P/S. Cells were
passaged after they reached 80% confluency. To detach cells from dishes, cells were washed with PBS and treated with 1-3 mL
0.05% trypsin/EDTA solution for approximately 5min. The reaction was halted by the addition of fresh DMEM. Cells were then diluted
in flasks or seeded in appropriate dishes for further experiments. For cultivation of the suspension Jurkat T cells and CARMA1-defi-
cient JPM50.6 T cells, RPMI medium supplemented with 10% FCS and 100 U/ml P/S was used. Jurkat T cells were maintained at a
density between 0.5x and 1.5x 106 cells/ml. Prior to each experiment, the cells were maintained at a density of approximately 1x 106
cells/ml. DLBCL cell lines were cultivated in RPMI medium supplemented with 15% FCS and 100 U/ml P/S. Cells were maintained at
a density between 0.5x and 1.5x 106 ells/ml. Primary murine and human CD4 T cells were cultured in RPMI medium supplemented
with 10% heat-inactivated FCS, 1% P/S, 1% NEAA, 1% HEPES (pH 7,4), 1% L-glutamine, 1% sodium pyruvate and 0.1% b-mer-
capto-ethanol.e4 Cell Reports 29, 873–888.e1–e10, October 22, 2019
Isolation and cultivation of primary murine CD4 T cells
For stimulation and knockdown experiments, primary murine CD4 T cells were isolated from spleen and lymph nodes (axial, inguinal
and neck) of MALT1 KO mice (MALT1tm1a(EUCOMM)Hmgu, ES cell clone HEPD0671_C08) by negative magnetic-activated cell sorting
(MACS) selection using the murine CD4 T cell isolation kit (Miltenyi Biotec). First, spleen and lymph nodes were placed in primary
T cell medium and ground through a cell strainer (100 mM). To separate the cells from residual tissue particles, the homogenate
was pelleted by centrifugation (300x g, 5 min). Afterward, the pellet was re-suspended in 500 ml DMEM and incubated with 5 mL
RBC lysis buffer (Miltenyi Biotec) for 2 min at RT, in order to destroy erythrocytes. Samples were washed, centrifuged and re-filtered
through a cell strainer to further eliminate residual tissue particles. CD4 T cells were then purified according to the manufacturer’s
protocol. The separated CD4 T cells were pelleted and re-suspended in an appropriate volume of primary T cell medium (cell density
0.5x 106 cells/ml). For expansion of primary murine CD4 T cells, the medium was supplemented with 1:5000 recombinant IL-2 (Pro-
leukinS, Novartis Pharma).
Isolation and cultivation of primary human CD4 T cells
For isolation of human CD4 T cells, blood was taken from healthy donors into S-Monovette (Sarstadt) columns containing Lithium-
Heparin. Blood was centrifuged (300x g, 10 min, RT, no break) to separate the plasma (upper layer), buffy coat (intermediate layer),
and erythrocytes (lowest layer). Following removal of the plasma fraction, the intermediate buffy coat layer containing leukocytes and
platelets was collected (approx. 10-18 ml/50 mL blood) and diluted with PBS up to a volume of 35 ml. To isolate mononuclear cells
(MNCs), diluted buffy coat was carefully layered onto 15mL Lymphoprep density gradient medium (StemCell Technologies, Inc.) and
centrifuged (160x g, 20min, RT, no break). About 20mL of supernatant was carefully removed and the sample was again centrifuged
(350x g, 20min, RT, no break). Finally, the intermediate layer containing theMNCswas collected andwashed twicewith PBMCbuffer
B1 (300x g, 8 min, 4C). CD4+ T cells were isolated by negative MACS selection using the human CD4 T cell isolation kit (Miltenyi
Biotec) according to the manufacturer’s instructions. Purified cells were re-suspended in primary T cell medium at a density of 2x
106 cells/ml and used for further stimulation experiments. Written consent and approval by the ethics board of the Medical Faculty
at the Technical University Munich was obtained for the use of peripheral blood from healthy donors.
METHOD DETAILS
Generation of CK1a-deficient Jurkat T cells
Jurkat T cells were transfected by electroporation with plasmid pX458 (Addgene #48138, gift F. Zhang) bearing Cas9 and designed
sgRNA (50- TGTACTTATGTTAGCTGACC) using a Gene Pulser Xcell (BioRad) (220 V, 1000 mF, 0.4 cm cuvettes). After 24 h of incu-
bation, EGFP-positive cells were sorted using a MoFlo sorting system (Beckman Coulter). Using serial dilution, selected cells were
plated in 96 well plates with a density of 0.5, 2 or 5 cells/well, and incubated for one to two weeks at 37C and 5%CO2. Growing cell
cloneswere then selected and further expanded. KO cell cloneswere initially identified by anti-CK1a staining byWestern Blot. Clones
lacking protein expression were genotyped by genomic PCR and sequencing.
Lentiviral transduction of Jurkat T cells
To generate stable MALT1-expressing cell lines, MALT1-deficient Jurkat T cells were lentivirally transduced with different pHAGE-
hDCD2-T2A-MALT1 constructs. First, lentivirus was produced by co-transfecting HEK293T cells with MALT1 expression plasmids
and lentiviral packaging vectors: 1.5x 106 HEK293T cells were seeded in a 10 cm2 dish in 8mL DMEMmedium one day prior to trans-
fection. The following day, HEK293T cells were transfected with 1 mg of the lentiviral envelope plasmid pMD2.G (Addgene #12259;
gift D. Trono), 1.5 mg of the packaging vector psPAX2 (Addgene #12260; gift D. Trono), and 2 mg MALT1 transfer plasmid (pHAGE-
hDCD2-T2A-MALT1-StrepTagII) using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics) according to the manufac-
turer’s instructions. After 3 days, the supernatant containing the virus particles was removed and sterile filtered (0.45 mM). 500 ml,
1000 ml or 1500 ml virus together with 8 mg/ml polybrene was added to 2x 105 MALT1-deficient Jurkat T cells. 24 h later, cells
were washedwith PBS (three times) and re-suspended in 1mL fresh RPMImedium. After one week in culture, transduction efficiency
was assessed by analyzing hDCD2 expression using flow cytometry, and by checking MALT1 expression levels via Western Blot.
When comparing several mutants similar expression levels were used.
Retroviral reconstitution of CD4 T cells from MALT1 KO mice
Retroviruses were produced in Phoenix cells transfected with pMSCV retroviral transfer vectors carrying human MALT1-FlagStrepII
constructs and Thy1.1 (separated by internal ribosome entry site (IRES) sequence). Virus supernatants were collected after 48 and
72 h and combined. Prior to the infection, CD4 T cells were stimulated for 48 h using hamster anti-murine anti-CD3 (0.5 mg/ml) and
hamster anti-murine anti-CD28 (1 mg/ml) on anti-hamster pre-coated plates. For infection, CD4 T cells were incubated for 6 h with
retroviral supernatant supplemented with Polybrene (8 mg/ml) and then washed using RPMI medium. Cultivation and expansion of
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Retroviral transduction of MALT1 shRNA and rescue in DLBCL
For retroviral transductions, DLBCL cell lines were transduced with a feline endogenous virus (FEV) to express a murine ecotropic
receptor using bleomycin as a selectable marker. To allow doxycycline-inducible small hairpin RNA (shRNA) expression, ecotropic
receptor-expressing cell lines were secondarily infected with a retrovirus expressing the bacterial tetracycline repressor (TETR)
using hygromycin as selection marker (Ngo et al., 2006). For the MALT1 rescue experiment, these cells were stably transduced
with a retroviral MALT1 shRNA (targeting sequence GTCACAGAATTGAGTGATTTC) cloned in pRSMX vector (Dai et al., 2017).
Expression of the shRNA was induced by adding 20 ng/ml doxycycline. Cells carrying the MALT1 shRNA were subsequently trans-
duced to constitutively express Strep-tagged MALT1 WT, MALT1 S559/562A, MALT1 S645/649A, MALT1 S803/805A or MALT1
6xSA together with aGFP reporter protein using a pMSCV-IRES-GFP plasmid. To ensure that only endogenousMALT1was knocked
down, the silent mutations in shRNA binding site of the exogenously expressed variants at cDNA position 313 (GAATTG to GAGTTA)
were introduced, without changing the amino acid sequence (Pelzer et al., 2013). The double-transduced cells weremonitored for live
GFP-positive cells by flow cytometry and normalized to the value at day 2 post retroviral transduction. Successful expression of the
different MALT1 variants was determined using Western Blotting.
Transfection in HEK293 cells
For overexpression experiments, HEK293 cells were transfected using standard calcium phosphate transfection protocols. 2.5x 106
HEK293 cells were seeded in a 10 cm2 dish on the day before transfection.
Electroporation of CARD11 KO Jurkat T cells
For overexpression experiments, CARD11 KO Jurkat T cells were electroporated using a Gene Pulser Xcell (BioRad) (220 V, 1000 mF,
0.4 cm cuvettes). 5 mg expression vectors for each construct were used and DNA amount was adjusted using empty expression con-
trol, if needed. 48 hours after electroporation, cells were lysed and HA-IP was performed.
Stimulation of Jurkat T cells and primary human CD4 T cells
Jurkat T cells and primary human CD4 T cells were stimulated with P/I (Phorbol 12-myristate 13-acetate (PMA)/Ionomycin) using a
concentration of 200 ng/ml PMA and 300 ng/ml Ionomycin. P/I stimulation acts downstream of TCR/CD28 as PMA directly stimulates
PKCq and Ionomycin triggers Ca2+ release from the endoplasmatic reticulum into the cytosol. Stimulation was performed in tubes at
37C. Anti-CD3/CD28 stimulation was performed in 300 ml medium using 1 mg/ml murine anti-human anti-CD3 antibody (IgG1) and
3 mg/ml murine anti-human anti-CD28 antibody (IgG2a). The antibodies were cross linked using 3 mg/ml of anti-mouse IgG1 and anti-
mouse IgG2a antibodies. Stimulation was performed in tubes at 37C. TNFa stimulation was performed in 2mLmedium using a con-
centration of 20 ng/ml. Stimulation was performed in tubes at 37C.
Stimulation of primary murine CD4 T cells
Primary murine CD4 T cells were stimulated with P/I or anti-CD3 and anti-CD28 antibodies in primary T cell medium. For P/I stimu-
lation, 200 ng/ml PMA and 300 ng/ml Ionomycin were used. Anti-CD3/CD28 stimulation was performed on pre-coated plates. There-
fore plates were coated with rabbit anti-hamster IgG (30 ml in 1 mL PBS per 6-well) over night at 4C. Afterward, plates were washed
twice with PBS before cells were stimulated with anti-CD3 (0.5 mg/ml) and anti-CD28 (1 mg/ml), and added to the pre-coated wells.
Cells were stimulated at a density between 1x – 5x 106 cells per ml.
Generation and analyses of NF-kB-EGFP reporter Jurkat T cells
Lentiviral NF-kB reporter was generated by introducing six copies of the NF-kB/Rel-binding site of the immunoglobulin k light chain
enhancer (ATCTGGGGATTCCCCA) and the conalbumin (cona)minimal promoter upstream of a hygromycin-EGFP-fusion gene
(pHAGE-Igk(6x)cona-HygEGFP), leading to NF-kB-dependent expression of EGFP (NF-kB-EGFP reporter) (Schmidt-Ullrich et al.,
1996). To generate parental and MALT1 KO Jurkat T cells expressing the NF-kB-EGFP reporter, cells were lentivirally transduced
as described above. Transduction efficiency of > 95% was assessed by analyzing EGFP expression following TNFa stimulation.
The generated MALT1 KO;NF-kB reporter Jurkat T cells were subsequently lentivirally transduced with different pHAGE-hDCD2-
T2A-MALT1B constructs as described before. Transduction efficiency of the second transduction was assessed by analyzing
hDCD2 expression using flow cytometry, and by checking MALT1 expression levels via Western Blot. Stimulation of generated
NF-kB reporter Jurkat T cells were performed in 500 ml medium in 24-well plates at 37C. Stimulation conditions were used as
described before, but adjusted to the respective medium volume. Cells were stimulated for the stated time and EGFP expression
was analyzed by FACS and quantified by gating on the number of EGFP positive cells.
Staining of surface molecules
To assess hDCD2 surface expression of infected CK1a- or MALT1-deficient Jurkat T cells, approximately 0.2x 106 cells were
collected and re-suspended in 400 ml FACS buffer (1x PBS, 2% FCS (w/v), 0.01% NaN3 (v/v)). Cells were stained with anti-CD2-
APC antibody (human, dilution 1:400) for 15 min at 4C in the dark. Samples were then washed with FACS buffer, taken up in ca.
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For staining of Thy1.1 expression in primary murine CD4 T cells, cells (0.2-1x 106) were collected after stimulation and were re-sus-
pended in FACS buffer. To prevent unspecific antibody binding to Fc receptors, samples were first treated with anti-CD16/32
(mouse, dilution 1:50) for 10 min at 4C. Afterward, staining with anti-Thy1.1-APC (1:200 dilution) was performed for 10-15 min at
4C in the dark. Samples were washed, resuspended in FACS buffer and acquired on Attune Cytometer.
Intracellular cytokine staining
For intracellular IL-2 staining, primarymurine CD4 T cells (1x 106) were stimulated for 5 h with P/I or anti-CD3/CD28 in the presence of
Brefeldin-A (10 ng/ml, Sigma) to prevent exocytosis of signaling molecules. After stimulation, cells were collected, centrifuged (300x
g, 5 min, 4C) and stained for the surface marker. Afterward, samples were washed and fixed in 1% PFA for 15 min at RT. Then, cells
were washed and permeabilized in IC buffer (0,2% saponin in 1x PBS) for 15min at RT. Unspecific antibody binding was blockedwith
anti-CD16/32 (mouse, dilution 1:50 in saponin buffer, 10 min, 4C) prior to incubation of samples with anti-IL-2-FITC or anti-IkBa
antibodies (both mouse, dilution 1:100 in IC buffer) for 30 min on ice. Cells were then washed (300x g, 5 min, 4C) and filled up
with FACS buffer to wash out unbound antibodies (> 15 min, RT). Anti-IkBa treated cells had to be stained with a secondary rat
anti-mouse-IgG1-FITC antibody (1:300, 20 min at 4C in the dark). Samples were again washed (300x g, 5 min, 4C), re-suspended
in FACS buffer and acquired on Attune Cytometer.
Quantitative analyses of NF-kB target gene induction
Positive retroviral transduced primary CD4 T cells expressing a human MALT1-FlagStrepII constructs and Thy1.1 surface marker
were purified using CD90.1 MicroBeads (Miltenyi) according to the manufacturer’s guide. Purified cells were cultured and expanded
for two more days as described above. 0.5x 105 cells were stimulated for 1 and 4 hours with anti-CD3 (0.05 mg/ml) and anti-CD28
(1 mg/ml) antibodies, and added to pre-coated wells (5 mg/ml rabbit anti-hamster IgG per 6-well; overnight at 4C). Afterward, cells
were collected, washed with PBS and the RNA was isolated using the RNeasy Kit (QIAGEN) according to the manufacturer’s guide.
RNAwas transcribed into cDNA using the Verso cDNA synthesis Kit (Thermo Fisher Scientific) according to themanufacturer’s guide.
For reverse transcriptase (RT)-PCR the Takyon qPCR Kit for SYBR Assays (Eurogentec) was used and the samples were measured
using a LightCycler 480 II instrument (Roche). The following primers were used: IL-2: fw – 50 TGAGCAGGATGGAGAATTACAG, rev –
50 GTGTTGTCAGAGCCCTTTAGTT; TNFAIP3/A20: fw – 50 CTACGACACTCGGAACTGGA, rev – 50 CAAACTTCTTAGCATTT
TGTCTG; NFKBIA/IkBa: fw – 50 CCTGCAGCAGACTCCACTC, rev – 50 GACACGTGTGGCCATTGTAG; b-Actin: fw – 50 CACACCCGC
CACCAGTTCG, rev – 50 CACCATCACACCCTGGTGC.
Preparation of whole cell lysates
For analysis of protein expression levels and activation of downstream signaling pathways including NF-kB DNA binding, 1 – 3x 106
cells were harvested (300 g, 5 min, 4C), washed with PBS, and subsequently lysed in 60-120 ml high salt buffer (20 mM HEPES (pH
7.9), 350 mM NaCl, 20% Glycerol (v/v),1 mMMgCl2, 0.5 mM EDTA, 0.1mM EGTA, 1% NP-40, 1mM DTT, 10 mM NaF, 8 mM b-Glyc-
erophosphate, 300 mM NaVanadate, Protease inhibitor mix). Lysates were incubated on a shaker for 20 min at 4C before insoluble
cellular debris was removed by centrifugation (14000 rpm, 15 – 30min, 4C). ForWestern Blot analysis, 4x SDS loading buffer (Roti-
Load1, Roth) was added and samples were boiled for 5 min at 95C. Aliquots for electrophoretic mobility shift assay (EMSA) were
taken before the addition of 4x SDS loading buffer and stored at 80C.
Co-immunoprecipitation (co-IP) and Strep-Tactin pulldown (ST-PD)
For protein interaction studies, 3-5x 107 cells were lysed in 800 ml Co-IP buffer (25 mMHEPES (pH 7.5), 150mMNaCl, 1 mMGlycerol,
0.2% NP-40 (v/v), 1 mM DTT, 10 mM NaF, 8 mM b-Glycerophosphate, 300 mM NaVanadate) supplemented with protease inhibitors.
Lysates were incubated for 20 min at 4C in an overhead rotator before samples were cleared by centrifugation (14 000 rpm, 15 min,
4C). 30 ml supernatant was collected as lysate control and was mixed with 4x SDS loading buffer (Roti-Load1, Roth) and boiled for
5 min at 95C. The residual supernatant was used for binding studies. Immunoprecipitations (IPs) were carried out by using antibodies
against BCL10 (C-17, 0,5 mg), CK1a (C-19, 1,5 mg or H-7, 2 mg or EPR19824, 7 ml), HA-tag (30 ml hybridoma supernatant of clone
12CA5, produced by Antibody Core Facility, HMGU), MALT1 (H300, 1,5 mg or B-12, 1,5 mg or 250 ml hybridoma supernatant of clone
21A2, produced by Antibody Core Facility, HMGU), MALT1 pS803 (250 ml hybridoma supernatant of clone 24A4, produced by Anti-
body Core Facility, HMGU) or NEMO/IKKg (FL-419, 1,5 mg) and samples were incubated in an overhead rotator overnight at 4C. After
antibody incubation, 18 ml rec-Protein G Sepharose 4B beads (1:1 suspension, life technologies) was added and lysates were rotated
for an additional 1-2 h at 4C. For Strep-Tactin pulldowns (ST-PDs), Strep-taggedCK1a, MALT1 orCARD11proteinswere precipitated
by using 30ml Strep-Tactin Sepharose (1:1 suspension, IBA) at 4Covernight. After incubationwith ProteinGSepharose or StrepTactin
Sepharose, beads were washed four times with 500 ml ice-cold Co-IP buffer without protease inhibitors (200x g, 5 min, 4C). The su-
pernatant was completely removed by aspiration and approx. 15 – 20 ml 2x SDS loading buffer (Roti-Load1, Carl Roth) was added to
the beads. Samples were boiled at 95C for 7 min before they were separated by SDS-PAGE and analyzed by Western Blotting.
Detection of active MALT1 using MALT1 activity based probes
MALT1 activity based probes (ABPs) were used to monitor cellular MALT1 activity. An ABP coupled to biotin (probe7: biotin-KLRSR-
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and lysed in 600 ml Co-IP buffer without protease inhibitors. Lysates were incubated for 20min in an overhead rotator before samples
were cleared by centrifugation (14 000 rpm, 15 min, 4C). 30 ml supernatant was collected as lysate control and was mixed with 4x
SDS loading buffer (Roti-Load1, Roth) and boiled for 5 min at 95C. The residual supernatant was pre-cleared using 12 ml High
Capacity Streptavidin Beads (Thermo Fisher) for 1 h at 4C. Subsequently, 0.1 mM ABP probe 7 was added to the residual
supernatant and incubated for 1 h at RT. To precipitate the active MALT1, 15 ml High Capacity Streptavidin Beads (Thermo Fisher)
were added for 1 h at 4C and afterward washed four times with 500 ml ice-cold Co-IP buffer without protease inhibitors (200x g,
5 min, 4C). The supernatant was completely removed by aspiration and approx. 15 – 20 ml 2x SDS loading buffer (Roti-Load1,
Carl Roth) was added to the beads. Samples were boiled at 95C for 7 min before they were separated by SDS-PAGE and analyzed
by Western Blotting.
Generation of anti-MALT1 S562, S649 and S803 phospho-specific antibodies
Monoclonal antibodies against MALT1 phosphorylation sites were generated by immunization of C57BL/6 mice and Lou/c rats with
ovalbumin-coupled peptides comprising phosphorylated serine S562, S649 or S803 (S562: EYSAEpSLVRNL, S649:
GSYLVpSKDLPK, S803: DEIPFpSFSDRL). Animals were injected subcutaneously and intraperitoneally with a mixture of 40 ug pep-
tides, 5 nmol CpG (Tib Molbiol, Berlin, Germany) and an equal volume of incomplete Freund’s adjuvant. A booster immunization was
performed 6 weeks later without Freund’s adjuvant and spleen cells were fused with P3X63Ag8.653 myeloma cells using standard
procedures. Hybriodma supernatants were screened in a solid-phase enzyme-linked immunosorbent assay (ELISA) for binding to the
respective phosphopeptides. Specificity was confirmed by negative screening on respective non-phosphorylated peptides. Positive
supernatants were further validated by western blot analysis. Hybridoma cells from selected supernatants were subcloned at least
twice by limiting dilution to obtain stablemonoclonal cell clones recognizing phosphorylated serines pS562 (clone 24E9; rat IgG2b/k),
pS649 (clone 29E12; mouse IgG2a/k) and pS803 (clone 24A4; rat IgG2c/k). Experiments were performed with hybridoma
supernatant.
Western Blotting
Proteins were transferred onto PVDF-membranes for immunodetection using electrophoretic semi-dry transfer system. After trans-
fer, membranes were blocked with 3% BSA or 5% milk for 1h at RT and incubated with specific primary antibody (dilution 1:1000 in
3%BSA/PBS-T or 5%milk/PBS-T) overnight at 4C.Membranes were washed in PBS-T before addition of HRP-coupled secondary
antibodies (1:7000 in 1.5%BSA or 2,5%milk in PBS-T; 1 h, RT). HRPwas detected by enhanced chemiluminescence (ECL) using the
LumiGlo reagent (Cell Signaling Technologies) according to manufacturer’s instructions.
Electrophoretic mobility shift assay
For electrophoretic mobility shift assays (EMSAs), double-stranded NF-kB or OCT1 binding sequences (H2K fw – 50 GATCC
AGGGCTGGGGATTCCCCATCTCCACAGG, H2K rev – 50 GATCCCTGTGGAGATGGGGAATCCCCAGCCCTG, OCT fw – 50 GATC
TGTCGAATGCAAATCACTAGAA, OCT rev – 50 GATCTTCTAGTGATTTGCATTCGACA) were labeled with [a-32P] dATP using Klenow
Fragment (NEB). To monitor DNA binding, whole cell lysates (3-6 mg) were incubated for 30 min at RT with shift-buffer (HEPES pH 7.9
(20mM), KCl (120mM), Ficoll (4%)), DTT (5mM), BSA (10 mg) and poly-dI-dC (2 mg, Roche) and radioactive probe (10000-20000 cpm).
Samples were separated on a 5% polyacrylamide gel in TBE buffer, vacuum-dried and exposed to autoradiography. Images have
been cropped for presentation.
NF-kB luciferase and EGFP reporter assays
Jurkat T cells reconstituted with empty vector (mock), CK1aWT or D136N mutant were transfected by electroporation with a 6x NF-
kB reporter plasmid (expressing Firefly luciferase) as well as a pTKluc plasmid (expressing Renilla luciferase) (220 V, 1000 mF, 0.4 cm
cuvettes). 72 h after transfection, 2x 106 cells were stimulated for 5 hwith P/I or anti-CD3/CD28 antibodies and lysed in 100 ml passive
lysis buffer (PLB, Promega). A dual luciferase assay (Promega) was performed according to the manufacturer’s protocol and lucif-
erase activity was determined using a luminometer (LB 960, Berthold).
CARD11-deficient line JPM50.6 expressing the NF-kB-EGFP reporter (Wang et al., 2002) were lentivirally transduced with pHAGE-
hDCD2-T2A-CARD11 and pHAGE-hDCD2-T2A-CARD11 S608A. 7 days after transduction, infection efficiency was determined by
analyzing hDCD2 expression and by checking CARD11 expression levels in WB. To analyze NF-kB activity, 0.5x105 cells were stim-
ulated for 5h with P/I. Afterward, cells were washed with PBS, taken up in 300 ml PBS and NF-kB activity was visualized via EGFP
expression on an Attune Acoustic Focusing Cytometer.
Production and purification of recombinant proteins
N-terminally GST-tagged MALT1 325-760 was expressed in E. coli BL21-CodonPlus (DE3)-RIPL cells and purified via affinity chro-
matography using GSTrap High Performance columns (GE Healthcare). Bacteria were grown in LB-medium at 37C with 100 mg/mL
ampicillin and 25 mg/mL chloramphenicol to an OD600 of 0.6-0.8, then moved to 18C and rotated for an additional 30 min before
induction with 50 mM IPTG. Protein was produced overnight (18C, 150 rpm). Cells were harvested and resuspended in 7 mL of lysis
buffer (50 mM HEPES pH 7.5, 10% (v/v) glycerin, 0.1% (v/v) Triton X-100, 150 mM NaCl, 2 mM MgCl2 x 6H2O, 1 mM DTT, protease
inhibitor cocktail (Roche)). The cell suspension was lysed by sonication and subsequently centrifuged for 30 min (16,500 rpm, 4C).e8 Cell Reports 29, 873–888.e1–e10, October 22, 2019
The supernatant was transferred to a new tube, and centrifugation was repeated for 60min. The Supernatant containing recombinant
MALT1 protein was applied to the A¨KTA and unspecifically bound proteins werewashed through the columnwith wash buffer (50mM
Tris, 150mMNaCl, pH 8.0). MALT1 was eluted with elution buffer (wash buffer with 15mM glutathione). The eluate was concentrated
to 600-800 mL using Amicon cellulose membrane filters (Merck) and protein concentration was determined using a NanoDrop
(Thermo Fisher).
Generation of MALT1 protein using the baculoviral expression system
His6-tagged MALT1 (aa 334-824)-HA was expressed in Sf9 cells using the baculovirus expression system (Sun et al., 2004). The pro-
tein was purified using nickel affinity chromatography (Ni-NTA agarose) according to the manufacturer’s instructions (QIAGEN).
In vitro kinase assay
150 ng recombinant CK1a (Sigma-Aldrich) was incubated with 5 mg bacterial produced and purified GST-MALT1 (aa 325-760) or 5 mg
baculoviral produced and purified 6xHis-MALT1-GyrB-HA (aa 334-824). Proteins were added into 20 ml kinase assay buffer (25 mM
MOPS (pH 7.2), 12.5 mM glycerol-2-phosphoate, 25 mM MgCl2, 5 mM EGTA and 2 mM EDTA. Immediately prior to use, DTT was
added to a final concentration of 0.25 mM). An ATP-containing assay cocktail was simultaneously prepared according to the man-
ufacturer’s guide, and 5 ml of this mix was added to the samples. In this approach non-radioactive ATP was used. The reaction
mixture was incubated for 2 h at 30C, then 4x SDS loading buffer was added and the samples boiled for 5 min. 10 ml sample
was loaded onto a 12,5% SDS-PAGE. Phosphorylation of MALT1 on S562 was detected using the specific anti-pS562 antibody
in Western Blot.
Sample preparation for phospho-peptide analyses of MALT1
For mass spectrometric analyses, Jurkat T cells were stimulated and MALT1 was enriched by ST-PD against MALT1 as described
earlier. The eluates were diluted to 200 ml with ABC buffer (50 mM ammonium bicarbonate) and digested by a modified filter aided
sample preparation (FASP)method (Wisniewski et al., 2009) as described in Grosche et al. (2016). Briefly, samples were reducedwith
20 ml DTT (100 mM) for 30 min at RT (shaking), followed by alkylation of cysteine residues with 50 ml Iodoacetamide (300 mM) for
30 min at RT in the dark. Urea buffer (8 M Urea/0.1 M Tris/HCl (pH 8.5)) was added to a final concentration ofR 4 M and samples
were loaded onto a 30 kDa cut-off filter (Nanosep 30k OMEGA, Pall Life Sciences, Ann Arbor), that had been previously equilibrated
with 200 ml UA buffer, and centrifuged at 14,000 g for 15-30min. After sample loading, filters werewashed three timeswith 200 ml urea
buffer and twice with 100 ml ABC buffer. Digestion was performed with 2 mg Lys-C (Wako Chemicals, Neuss) in 70 ml ABC buffer con-
taining phosphatase inhibitors (Phosphatase Inhibitor Cocktails 2 & 3, 1:100 (v/v), Sigma-Aldrich) for 2 h at RT followed by tryptic (5mg,
Sigma-Aldrich) digest at 37C for 16 h. Digested peptides were collected by centrifugation at 16,000 g for 15 min and residual pep-
tides were eluted from the filters with 20 ml 50 mM ABC/2% ACN. Combined eluates were concentrated to 40-50 ml in a vacuum
centrifuge (Univapo 150 ECH, UniEquip, Martinsried).
For phospho-peptide enrichment, TiO2 beads (Sachtopore NP, 5mm, 300A˚ (SNX030S005), Sachtleben Chemie, Duisburg) were
resuspended in water at 125 mg/ml, and 20 ml per sample was washed sequentially with 400 ml water, 400 ml ACN and equilibrated
in 400 ml washing buffer (60% ACN/4% TFA) by centrifugation at 15,000 g for 1 min. The peptide eluates were diluted with 160 ml
loading buffer (80% ACN/5% TFA) and incubated with the bead preparation for 90 min at RT (shaking). The supernatant containing
unbound peptides was discarded after centrifugation and the beads were washed three times for 2 min at RT with 200 ml 50% ACN/
0.1% TFA. Enriched phospho-peptides were then eluted twice with 20 ml NH4OH (10%) for 10 min at RT (shaking) by centrifugation
(21,000 g, 3min) and the combined eluates were acidified with TFA to pH 2.
LC-MS/MS data acquisition
Enriched phospho-peptides were analyzed on an Ultimate 3000 nano HPLC system (Dionex, Sunnyvale, CA) coupled to a LTQ Orbi-
trap XL mass spectrometer (Thermo Fisher Scientific), equipped with a nano-ESI source.
20 ml of each enriched sample was injected automatically and peptides were loaded onto a nano trap column (5 mm x 300 mm i.d.,
packed with 5 mm Acclaim PepMap100 C18 resin, 100 A˚ pore size (LC Packings, Sunnyvale)) at a flow rate of 30 ml/min using 7%
ACN/0.1% FA (v/v) in HPLC-grade water for 5 min. Separation of peptides was performed on a reversed-phase analytical column
(15 cm x 75 mm i.d., Acclaim PepMap C18 resin, 3 mm, 100 A˚ pore size (Dionex)) at a constant temperature of 40C and peptides
were eluted using the following gradient conditions at a flow rate of 300 nl/min: linear from 7% ACN to 32% ACN over 60 min, linear
from 32% ACN to 93% ACN in 1 min and isocratic at 93% ACN for 5 min, followed by an equilibration step for 15 min at starting
conditions (all ACN buffers included 0.1% (v/v) FA).
Ionization of peptides was performed in a nano-ESI source using 1.51 kV spray voltage and a capillary temperature of 200C. The
mass spectrometer was operated in data-dependent acquisition mode, and up to the ten most intense precursor ions were selected
for fragmentation. The signal of polysiloxan (m/z = 445.12002) was used as lock mass for internal calibration. Full scan MS spectra
were acquired in the Orbitrap mass analyzer within an m/z range from 300 to 1500 with a resolution of 60,000 at m/z 400. The AGC
target value for precursor ions was set to 1e6 and ions were collected up to amaximum of 500ms. Up to ten precursors with a charge
state ofR 2 were isolated in a window of 2 Th and selected for fragmentation by CID in the linear ion trap if a minimal ion count of 200
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were acquired with a resolution of 15,000 at m/z 400 and an AGC target value of 1e4 with a maximal injection time of 100 ms. After
MS/MS analysis, precursor ions were dynamically excluded for 30 s.
Mass spectrometric raw data processing and analyses
Mass spectrometric raw data was analyzed with Proteome Discoverer Software (Version 1.4.1.14, Thermo Fisher Scientific) using
Mascot (Version 2.5.1, Matrix Science, London) as a search engine. MS/MS spectra were searched against Ensembl Human data-
base (Release 80, May 2015) with a precursor mass tolerance of 7 ppm and a fragment mass tolerance of 0.7 Da, carbamidomethy-
lation (C) as static modification, and deamidation (N,Q), oxidation (M) and phosphorylation (S, T, Y) as dynamic modifications.
Enzyme specificity was set to trypsin and up to two missed cleavages were allowed. For the confident localization of phospho-sites,
the phosphoRS (Version 3.0) node was included in the Proteome Discoverer workflow. MALT1 identifications were adjusted to < 1%
FDR at PSM level based on Percolator q-Value.
QUANTIFICATION AND STATISTICAL ANALYSES
For statistics all experiments in CD4 and Jurkat T cells contained at least four biological replicates and values represent the mean ±
standard deviation (SD). Experiments were analyzed by using unpaired Student’s t test. Statistical significance p values are:
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. For statistics of DLBCL cell growth, error bars depict standard errors of the
mean (SEM) over 4 biological replicates for each time point and vector. For each time point, we first computed the ratio rVtoNoV: =
nV/nNoV of living cells having the vector (nV) to living cells not having the vector (nNoV) from the measured ratio rVL of cells having
the vector in the subset of all living cells. As nV+nNoV = nAllLiving, i.e., 100% with respect to the scale of rVL, we have nV/nNoV = rVL/
(1-rVL). Second, for each two-days-interval between two measured time points, we then computed the relative cell growth or dying
rates of with versus without vector: rescueRate: = rVtoNoV(t+2days)/rVtoNoV(t). If rescuing takes place in a given 2-day time interval,
cells with the vector will grow faster or die slower than cells without the vector, i.e., the rescue rate will be > 100% for this time interval.
As these rescue rates are multiplicatively defined, we log2-transformed them to obtain normally distributed values: l2rescueRate: =
log2(rescueRate). To determine the rescue effects that are consistent over time versus the MALT1 WT vector, we finally compared
l2rescueRate(for a given MALT1 mutant vector) with l2rescueRate(for MALT1 WT) via t tests (paired over time points, one-tailed).
Notably, these paired comparisons automatically normalize for any vector-independent effects on cell growth/death rates that affect
both compared vectors and are shown by the empty vector curve.
DATA AND CODE AVAILABILITY
The published article includes all data generated or analyzed during this study. Original source data for Figures in the paper are avail-
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